Blurbs

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and Inhibrx (INBX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALTResearch Report) and Inhibrx (INBXResearch Report) with bullish sentiments.

Altimmune (ALT)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Altimmune today and set a price target of $26.00. The company’s shares closed last Thursday at $8.79.

According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -15.8% and a 24.4% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Altimmune with a $31.33 average price target, implying a 232.6% upside from current levels. In a report issued on November 4, B.Riley Financial also reiterated a Buy rating on the stock with a $26.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Inhibrx (INBX)

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Inhibrx today and set a price target of $40.00. The company’s shares closed last Thursday at $29.20.

According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.9% and a 33.7% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Inhibrx has an analyst consensus of Strong Buy, with a price target consensus of $49.40, implying a 50.8% upside from current levels. In a report issued on November 8, Credit Suisse also maintained a Buy rating on the stock with a $46.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More